December 3rd 2024, 8:00pm
In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.
November 14th 2024, 4:00pm
The advantages and disadvantages of CAR-T cell therapy should be carefully thought about for patients with melanoma.
November 13th 2024, 2:00pm
An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment option for melanoma.
October 31st 2024, 7:00pm
Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates compared to those treated with placebo.
October 2nd 2024, 1:00pm
An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved progression and survival.
October 1st 2024, 9:00pm
Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.
October 1st 2024, 3:00pm
Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid cancer and breast cancer.
September 25th 2024, 1:00pm
Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.
September 5th 2024, 3:00pm
The Food and Drug Administration granted a fast track designation to IBI363 for patients with unresectable advanced or metastatic melanoma.
September 4th 2024, 9:00pm
A new algorithm has found that combining immune checkpoint inhibitors bolsters immune response among some patients with advanced melanoma.
FDA Approves Initiation of a New Trial in Recurrent Glioblastoma
The Benefit of Clinical Trial Enrollment for Patients With Cancer
Addressing Gaps, Challenges and Disparities in AYA Cancer Care
Unexpected Challenges 11 Years After Breast Cancer
